Reviews/GLP-1 Receptor Agonists/Reduce obstructive sleep apnoea
Novel · GLP1-NOV-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The strongest evidence here comes from a two-part phase-3 trial program in people with obesity and moderate-to-severe sleep apnoea, which tested the drug both in patients not using a CPAP breathing machine and in patients who were, and found large reductions in the number of breathing interruptions per hour of sleep in both settings [1][19]. Most treated participants moved to a milder severity category, and a meaningful share ended up with no detectable sleep apnoea [20]. Two further trials of liraglutide, a drug that is purely a GLP-1 receptor agonist, point the same way: one in patients not using CPAP [6] and one in diabetic patients on CPAP [3]. The panel landed high because the effect is large, measured by sleep studies, and reproduced across trials designed specifically to separate the CPAP and non-CPAP settings. It held back from the very top because most of the pivotal data come from tirzepatide, which is a combined GIP and GLP-1 drug rather than a pure GLP-1 agonist, and because so much of the evidence sits inside a single trial program.
Two phase-3 RCTs of tirzepatide in obese moderate-to-severe OSA report AHI treatment differences of -20.0 events/h without PAP and -23.8 events/h with PAP, each versus placebo and both p<0.001 [1], with the result stated to hold 'with and without PAP therapy' [19]. Severity-category improvement occurred in 67.7% (no-PAP) and 79.0% (on-PAP) of tirzepatide-treated participants, and 20-32% reached the no-OSA category [20], with reductions seen across every baseline subgroup [21]. Pure GLP-1 receptor agonist evidence comes from SCALE, where liraglutide 3.0 mg gave a significantly greater AHI reduction than placebo in 359 obese patients unwilling or unable to use CPAP [6], and from a 90-patient RCT where liraglutide added to CPAP significantly lowered AHI in diabetic patients with severe OSA [3]. The magnitude of AHI change tracked achieved weight reduction [14]. The contested point: The division is whether this corpus certifies 'GLP-1 receptor agonists' as a class: the large-effect pivotal data are all tirzepatide, a GIP/GLP-1 co-agonist [1][14][16][19][20][21], while the only pure-GLP-1-RA support is a 2014 conference abstract whose AHI figure sits in an unseen table [6] and a single small trial in which both arms received CPAP [3]. The CPAP-independence clause therefore rests on the tirzepatide two-ISA design and SCALE's non-CPAP population, since the liraglutide-plus-CPAP trial [3] does not test independence at all.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal evidence ([1],[9],[14],[16],[19],[20],[21]) is tirzepatide, a dual GIP/GLP-1 receptor co-agonist, not a pure GLP-1 receptor agonist; reading the class label strictly, these do not directly certify 'GLP-1 receptor agonists'.
Evidential independence is weak: the large majority of the corpus is a single program (SURMOUNT-OSA). Pure-GLP-1-RA support reduces to [6] (2014 conference abstract whose numeric AHI effect is in an unseen Table) and [3] (N=90 single small trial).
Where it remains uncertain. The pivotal effect is carried by tirzepatide, a dual GIP/GLP-1 agonist concentrated in one trial program [1][14][16][19][20][21], leaving pure GLP-1 receptor agonist evidence resting on a numerically incomplete abstract [6] and a single small trial [3].
Aleatory
AHI reductions ranged widely across baseline subgroups (e.g. -12.1 to -52.2 events/h by baseline AHI severity) [21], so individual response is not uniform.
Epistemic
Only two pure GLP-1 RA trials exist here: SCALE [6], whose numeric AHI effect is confined to an unseen table, and a single N=90 trial [3].
Inferential
Extending tirzepatide's dual GIP/GLP-1 results [1] to the pure 'GLP-1 receptor agonist' class is an inference the corpus does not directly license.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT effect: large AHI reduction vs placebo in no-PAP obese OSA patients (trial 1).
“Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2.”
Panel auditInternal validity: high · scope of inference: Adults with moderate-to-severe OSA and obesity (mean AHI ~50, BMI ~39), on tirzepatide a dual GIP/GLP-1 agonist, over 52 weeks, both with and without PAP.Key limitations: tirzepatide is a dual GIP/GLP-1 agonist, not a selective GLP-1 RA · N not stated in abstract · 52-week horizon
Second pure GLP-1 RA (liraglutide) RCT confirming AHI reduction, here added to CPAP.
“After 3 months, the body mass index (BMI), apnea hypopnea index (AHI), and mean systolic blood pressure in the liraglutide treatment group were significantly lower than those in the control group (P < 0.05).”
Panel auditInternal validity: medium · scope of inference: T2DM patients with severe OSA, all on CPAP; speaks to liraglutide added to CPAP, not to effect without CPAP.Key limitations: both arms on CPAP, cannot show CPAP-independence · T2DM not obesity population · small n, short follow-up · blinding not stated
Pure GLP-1 RA (liraglutide) RCT in a non-CPAP obese population, with AHI reduction significantly greater than placebo.
“Obese individuals (n = 359) without diabetes who had moderate or severe OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomised 1:1 to liraglutide 3.0 mg or placebo for 32 weeks”
Panel auditInternal validity: high · scope of inference: Obese non-diabetic adults with moderate/severe OSA unwilling/unable to use CPAP; the clearest exact match to the claim for a selective GLP-1 RA.Key limitations: effect-size numbers reported only in unshown Table · 32-week horizon · conference abstract
A rationale-and-design paper; the abstract describes endpoints and baseline characteristics but reports no AHI outcome.
Panel auditInternal validity: not assessable from abstract · scope of inference: Describes the planned evaluation of tirzepatide in moderate-to-severe OSA with obesity; no outcome inference possible.Key limitations: no results · design paper only
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated, polysomnography-measured, large-effect RCT evidence carries the AHI-reduction-in-obesity-independent-of-CPAP claim, with the dual-agonist label and single-program concentration the only material deductions.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Pure GLP-1 RA RCT with reported AHI effect in non-CPAP patients. The class claim currently leans on tirzepatide [1]; the only non-CPAP pure-GLP-1-RA trial reports no extractable AHI number [6]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A phase-3 polysomnography RCT of a pure GLP-1 RA (e.g. semaglutide or liraglutide) versus placebo in obese OSA patients not using CPAP, with the full AHI treatment difference reported.
Open question: Does a pure GLP-1 receptor agonist produce an AHI reduction of comparable magnitude to the GIP/GLP-1 co-agonist in obese OSA? Why it is still open: The large-effect data are tirzepatide [1][19]; the pure-GLP-1-RA trials here are an abstract with no extractable AHI number [6] and a single N=90 study [3].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19